340B—Where Do We Go From Here?-Reference-Cited by-同舟云学术

340B—Where Do We Go From Here?

Published:2023-08-15 Issue:7 Volume:330 Page:593
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Kishore Sanjay¹²,Nayak Rahul K.³,Kesselheim Aaron S.⁴⁵

Affiliation:

1. The Equal Justice Initiative, Montgomery, Alabama

2. The University of Alabama at Birmingham

3. Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia

4. Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women’s Hospital, Boston, Massachusetts

5. Harvard Medical School, Boston, Massachusetts

Abstract

This Viewpoint summarizes inefficiencies in the 340B program and provides suggestions for equitable reform that will potentially benefit patients.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2808049/jama_kishore_2023_vp_230079_1691609255.51098.pdf

Reference9 articles.

1. Relationship between initiation of 340B participation and hospital safety-net engagement.;Nikpay;Health Serv Res,2020

2. Perverse incentives—HIV prevention and the 340B drug pricing program.;Marcus;N Engl J Med,2022

3. Budgetary impact analysis of a primary care-based hepatitis C treatment program: effects of 340B drug pricing program.;Jones;PLOS One,2019

4. Essential but undefined—reimagining how policymakers identify safety-net hospitals.;Chatterjee;N Engl J Med,2020

5. Mulligan? K. The 340B drug pricing program: background, ongoing challenges and recent developments. October 12, 2021. Accessed May 26, 2023.? https://healthpolicy.usc.edu/research/the-340b-drug-pricing-program-background-ongoing-challenges-and-recent-developments/

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interpreting 340B contract pharmacy growth: who really benefits?;Health Affairs Scholar;2023-12-09